View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	May 06, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Trading Symbol	CLXT
Entity Registrant Name	CALYXT, INC.
Entity Central Index Key	0001705843
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		32,702,339

BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 84,231	$ 93,794
Restricted cash	381	381
Trade accounts receivable	124
Due from related parties	130	46
Inventory	379
Prepaid expenses and other current assets	1,778	1,301
Total current assets	87,023	95,522
Non-current restricted cash	1,120	1,113
Land, buildings, and equipment	21,854	21,850
Other non-current assets	674	306
Total assets	110,671	118,791
Current liabilities:
Accounts payable	724	818
Accrued expenses	1,610	2,007
Accrued compensation and benefits	887	1,305
Due to related parties	875	1,905
Current portion of financing lease obligations	264	258
Other current liabilities	290	711
Total current liabilities	4,650	7,004
Financing lease obligations	18,162	18,227
Other non-current liabilities	156	163
Total liabilities	22,968	25,394
Stockholders' equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized; 32,707,725 shares issued and 32,692,189 shares outstanding as of March 31, 2019, and 32,664,429 shares issued and 32,648,893 shares outstanding as of December 31, 2018	3	3
Additional paid-in capital	177,750	176,069
Common stock in treasury, at cost; 15,536 shares	(230)	(230)
Accumulated deficit	(89,820)	(82,445)
Total stockholders' equity	87,703	93,397
Total liabilities and stockholders' equity	$ 110,671	$ 118,791

BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	32,707,725	32,664,429
Common stock, shares outstanding	32,692,189	32,648,893
Treasury stock, shares	15,536	15,536

STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenue	$ 157	$ 11
Operating expenses:
Cost of revenue	34
Research and development	2,044	1,048
Selling, general and administrative	5,241	2,676
Management fees and royalties	361	583
Total operating expenses	7,680	4,307
Loss from operations	(7,523)	(4,296)
Interest, net	172	(68)
Foreign currency transaction loss	(24)	(6)
Loss before income taxes	(7,375)	(4,370)
Income taxes	0	0
Net loss	$ (7,375)	$ (4,370)
Basic and diluted loss per share	$ (0.23)	$ (0.16)
Weighted average shares outstanding - basic and diluted	32,677,944	27,851,162

STATEMENTS OF STOCKHOLDER'S EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares in Treasury [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2017	$ 57,476	$ 3	$ 112,021		$ (54,548)
Beginning balance, shares at Dec. 31, 2017		27,718,780
Issuance of common stock	$ 0	$ 0	$ 0	$ 0	$ 0
Issuance of common stock, shares	0	0	0	0	0
Shares purchased	$ 0	$ 0	$ 0	$ 0	$ 0
Shares purchased, shares	0	0	0	0	0
Stock options exercised	$ 714		$ 714
Stock options exercised, shares		236,001
Expense for all awards vesting in period, net of forfeitures and modifications	40		40
Net loss	(4,370)				$ (4,370)
Ending balance at Mar. 31, 2018	53,860	$ 3	112,775		(58,918)
Ending balance, shares at Mar. 31, 2018		27,954,781
Beginning balance at Dec. 31, 2018	93,397	$ 3	176,069	$ (230)	(82,445)
Beginning balance, shares at Dec. 31, 2018		32,648,893
Issuance of common stock	$ 0	$ 0	$ 0	$ 0	$ 0
Issuance of common stock, shares	0	0	0	0	0
Shares purchased	$ 0	$ 0	$ 0	$ 0	$ 0
Shares purchased, shares	0	0	0	0	0
Stock options exercised	$ 125		$ 125
Stock options exercised, shares	34,402	43,296
Expense for all awards vesting in period, net of forfeitures and modifications	$ 1,556		1,556
Net loss	(7,375)				$ (7,375)
Ending balance at Mar. 31, 2019	$ 87,703	$ 3	$ 177,750	$ (230)	$ (89,820)
Ending balance, shares at Mar. 31, 2019		32,692,189

STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating activities
Net loss	$ (7,375)	$ (4,370)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	342	156
Stock-based compensation	1,556	40
Unrealized foreign exchange gain		8
Changes in operating assets and liabilities:
Trade accounts receivable	(124)
Due to/from related parties	(1,114)	(496)
Inventory	(379)
Prepaid expenses and other assets	(624)	(880)
Accounts payable	(94)	(310)
Accrued expenses	(397)	182
Accrued compensation and benefits	(418)	(456)
Other accrued liabilities	(708)	(439)
Net cash used by operating activities	(9,335)	(6,565)
Investing activities
Purchases of land, buildings and equipment	(346)	(41)
Net cash used by investing activities	(346)	(41)
Financing activities
Deferred offering costs		(69)
Proceeds from the exercise of stock options	125	714
Net cash provided by financing activities	125	645
Net decrease in cash, cash equivalents and restricted cash	(9,556)	(5,961)
Cash, cash equivalents and restricted cash - beginning of period	95,288	56,664
Cash, cash equivalents and restricted cash - end of period	$ 85,732	$ 50,703

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	1. BASIS OF PRESENTATION Our unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In our opinion, the accompanying financial statements reflect all adjustments necessary for a fair presentation of our statements of financial position, results of operations and cash flows for the periods presented. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the audited financial statements and notes thereto included in our Annual Report filed with the Securities and Exchange Commission (SEC) on March 12, 2019. The accompanying Balance Sheet as of December 31, 2018 was derived from the audited financial statements but it does not include all disclosures required by U.S. GAAP for a full set of financial statements. This Form 10-Q should be read in conjunction with the Company’s financial statements and notes included in the Annual Report on Form 10-K filed on March 12, 2019, as referenced above. We are only highlighting in this Form 10-Q the material changes from our disclosures in our Annual Report. *Inventory* Inventories are recorded at the lower of cost or net realizable value and include all costs of seed production and grain we purchase as well as costs to transport and process the grain into finished products. Consideration we receive from our growers to purchase seed is reduction in the cost of inventory. We evaluate inventory balances for obsolescence quarterly using projected selling prices for our products, market prices for the underlying agricultural markets, the age of products, and other factors considering our limited operating history. Effective January 1, 2019, we designated all seed and grain production agreements as normal purchases and as a result no longer consider these agreements to be accounting derivatives. As a result, we no longer reflect these agreements at fair value. As of that date, any mark-to-market gains or losses were frozen on our balance sheet and will be reflected in inventory upon delivery as part of the cost of the associated grain. Prior to the commercialization of our High Oleic Soybean Products in late February 2019, we expensed all costs associated with the production of seed and acquisition of grain, net of proceeds from seed sales, as research and development (R&D) expense. *Revenue Recognition* We recognize sales revenue at the point in time control transfers to the customer, which is based on shipping terms. Sales include shipping and handling charges if billed to the customer and are reported net of trade promotion and other costs, including estimated allowances for returns, unsalable product, and prompt pay discounts. Sales, use, value-added and other excise taxes are not recognized in revenue. Trade promotions are recorded based on estimated participation and performance levels for offered programs at the time of sale. We generally do not allow a right of return. However, on a limited case-by-case basis with prior approval, we may allow customers to return product. We also recognize revenue from R&D agreements and license agreements. Revenues from R&D agreements may consist of nonrefundable up-front payments, milestone payments, royalties, and services. In addition, we may license our technology to third parties, which may or may not be part of an R&D agreement. Nonrefundable up-front payments are deferred and recognized as revenue over the term of the R&D agreement. If an R&D agreement is terminated before the original term of the agreement is fulfilled, all remaining deferred revenue is recognized at termination. Milestone payments represent amounts received from our R&D partners, the receipt of which is dependent upon the achievement of certain scientific, regulatory, or commercial milestones. We recognize milestone payments when the triggering event has occurred, there are no further contingencies or services to be provided with respect to that event, and the counterparty has no right to refund of the payment. *Stock-Based Compensation* We measure employee stock-based awards at grant-date fair value and record compensation expense over the vesting period of the award. Grants to nonemployees were previously remeasured each reporting period. Following the adoption of the new accounting pronouncement as discussed below, as of January 1, 2019, we no longer remeasure these awards as the fair value is determined on the grant date *Recently Adopted Accounting Pronouncements* In the first quarter of 2019, we adopted new accounting requirements for recognition of revenue from contracts with customers. We adopted these requirements using the cumulative effect approach. The adoption did not have an impact on our financial statements. In the first quarter of 2019, we adopted new accounting requirements for share-based payment transactions for acquiring goods and services from nonemployees. The adoption did not have an impact on our financial statements as each of the share-based payment awards granted to nonemployees had a measurement date upon grant, and thus no cumulative adjustment to retained earnings was required.

Financial Instruments, Fair Value, and Concentrations of Credit Risk

3 Months Ended

Mar. 31, 2019

Text Block [Abstract]

Financial Instruments, Fair Value, and Concentrations of Credit Risk

2. FINANCIAL INSTRUMENTS, FAIR VALUE, AND CONCENTRATIONS OF CREDIT RISK

The carrying values of cash and cash equivalents, restricted cash, due from related parties, accounts payable, due to related parties, and all other current liabilities approximate fair value. The fair value of our financing lease obligations, including the current portion, are $15.6 million as of March 31, 2019, and $15.8 million as of December 31, 2018. The carrying amounts of our financing lease obligations, including the current portion, were $18.4 million as of March 31, 2019, and $18.5 million as of December 31, 2018. The fair value of our financing lease obligations was determined using discounted cash flow analysis based on market rates for similar types of borrowings. Financing lease obligations are a Level 2 liability in the fair value hierarchy.

Fair Value Measurements and Financial Statement Presentation

As a result of the designation made on January 1, 2019, as described in Note 1 to these financial statements, our forward purchase contracts are no longer carried at fair value.

The fair values of our assets, liabilities, and derivative positions recorded at fair value and their respective levels in the fair value hierarchy as of December 31, 2018, were as follows:


	December 31, 2018								December 31, 2018
	Fair Values of Assets								Fair Values of Liabilities
In Thousands	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total

Other items reported at fair value:
Forward Purchase Contracts (a)	$	-	$	1	$	-	$	1	$	-	$	248	$	-	$	248

Total	$	-	$	1	$	-	$	1	$	-	$	248	$	-	$	248

(a)	The fair value for forward purchase contracts is estimated based on commodity futures market prices.

Commodity Price Risk

We enter into purchase agreements for grain with settlement values based on commodity futures market prices. These agreements allow our counterparty to fix their sale prices to us at various times as defined in the contract. We do not currently hedge these floating or fixed rate exposures.

Foreign Exchange Risk

Foreign currency fluctuations affect our foreign currency cash flows related to payments to our Cellectis and third-party purchases. Our principal foreign currency exposure is to the euro. We do not currently hedge these exposures, and we do not believe that the current level of foreign currency risk is significant to our operations.

Concentrations of Credit Risk

We invest our cash, cash equivalents, and restricted cash in short-term highly liquid investments and hold deposits at financial institutions that may exceed insured limits. We evaluate the credit worthiness of these institutions in determining the risk associated with these deposits. We have not experienced any losses on these deposits.

Related-Party Transactions	3 Months Ended
Related-Party Transactions	Mar. 31, 2019
Related Party Transactions [Abstract]
Related-Party Transactions	3. RELATED-PARTY TRANSACTIONS We have several agreements that govern our relationship with Cellectis. Pursuant to our management services agreement with Cellectis, we also pay management fees for services they provide, primarily information technology, legal, human resources, finance and accounting, and communications services. We perform Cellectis’ U.S. operations payroll services. We incurred management fee expenses of $0.4 million for the three months ended March 31, 2019, and $0.6 million for the three months ended March 31, 2018. Cellectis also has guaranteed our headquarters lease agreement. Cellectis’ guarantee of our obligations under the sale-leaseback transaction will terminate at the end of the second consecutive calendar year in which our tangible net worth exceeds $300 million. We also license key technology from Cellectis and owe them royalties on any revenue we generate from sales of product as well as a percentage of any sublicense revenues we generate. Any amounts borrowed from Cellectis bear floating-rate interest at a rate of 12-month Euribor plus five percent per annum. TALEN technology was invented by researchers at the University of Minnesota and Iowa State University and exclusively licensed to Cellectis. We obtained from Cellectis an exclusive license for the TALEN technology for commercial use in plants. TALEN technology is the primary gene-editing technology used by us today. We incurred nominal license fees under these agreements in the three-month periods ended March 31, 2019 and 2018.

Net Loss Per Share

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Net Loss Per Share

4. NET LOSS PER SHARE

Basic and diluted loss per share were calculated using the following:

All outstanding stock options and restricted stock units are excluded from the calculation since they are anti-dilutive.


	Three months ended March 31,
In Thousands, Except Share Data and Per Share Amounts	2019		2018

Net loss	$	(7,375)	$	(4,370)
Average number of common shares—basic and diluted EPS		32,677,944		27,851,162

Loss per share—basic and diluted	$	(0.23)	$	(0.16)


	2019		2018

Anti-dilutive stock options and restricted stock units		4,385,595		4,917,164

We have not used the treasury method in determining the number of anti-dilutive stock options and restricted stock units in the table above.

Stock-Based Compensation

3 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

5. STOCK-BASED COMPENSATION

We use broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management’s interests are aligned with those of our shareholders. We have also granted equity-based awards to nonemployees and certain employees of Cellectis.

In December 2014, we adopted the Calyxt, Inc. Equity Incentive Plan (the 2014 Plan), which allows for the grant of stock options, and in June 2017, we adopted the 2017 Omnibus Plan (the 2017 Plan).

As of March 31, 2019, 896,478 shares were registered and available for grant under effective registration statements, while, 4,159,660 shares were available for grant in the form of stock options, restricted stock, and restricted stock units under the 2017 Plan. Stock-based awards currently outstanding also include some granted under the 2014 Plan, under which no further awards will be granted.

Stock Options

The estimated fair values of stock options granted and the assumptions used for the Black-Scholes option pricing model were as follows:


	Three months ended March 31,

	2019		2018

Estimated fair values of stock options granted	$	9.45	$	10.39
Assumptions:
Risk-free interest rate		2.5%		2.5% - 2.7%
Expected volatility		78.9%		40.9% - 53.7%
Expected term (in years)		6.9 years		6.5 – 9.2 years

We estimate the fair value of each option on the grant date or other measurement date if applicable using a Black-Scholes option-pricing model, which requires us to make predictive assumptions regarding future stock price volatility, employee exercise behavior and dividend yield. The risk-free interest rate for periods during the expected term of the options is based on the U.S. Treasury zero-coupon yield curve in effect at the time of grant. We estimate our future stock price volatility using the historical volatility of comparable public companies over the expected term of the option. Our expected term represents the period of time that options granted are expected to be outstanding determined using the simplified method. We have not nor do we expect to pay dividends for the foreseeable future.

Option strike prices are set at 100 percent or more of the closing share price on the date of grant, and generally vest over six years following the grant date. Options generally expire 10 years after the date of grant.

Information on stock option activity follows:


	Options Exercisable		Weighted- Average Exercise Price Per Share		Options Outstanding			Weighted- Average Exercise Price Per Share

Balance as of December 31, 2018		1,278,038	$	7.45		3,201,887			$ 10.67
Granted						180,000			13.01
Exercised						(34,402	)		3.63
Forfeited or expired						(2,205	)		13.29

Balance as of March 31, 2019		1,340,631	$	7.59		3,345,280			$ 10.87

Stock-based compensation expense related to stock option awards was $0.8 million for the three months ended March 31, 2019, and $0.1 million for the three months ended March 31, 2018. The aggregate intrinsic value of options outstanding and exercisable at March 31, 2019, was $23.3 million and the weighted average remaining contractual term was 8.0 years as of that date.

Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows:


	Three months ended March 31,
In Thousands	2019		2018

Net cash proceeds	$	125	$	714

Intrinsic value of options exercised	$	353	$	3,260

Restricted Stock Units

Units settled in stock subject to a restricted period may be granted to key employees under the 2017 Plan. Restricted stock units generally vest and become unrestricted over five years after the date of grant.

Information on restricted stock unit activity follows:


	Number of Restricted Stock Units Outstanding			Weighted-Average Grant Date Fair Value

Unvested balance at December 31, 2018		1,051,414		$	10.15
Vested		(8,894	)		14.91
Unvested balance at March 31, 2019		1,042,520		$	9.64

The total grant-date fair value of restricted stock unit awards that vested was $0.1 million for three months ended March 31, 2019, and zero for three months ended March 31, 2018.

As of March 31, 2019, unrecognized compensation expense related to non-vested stock options and restricted stock units was $10.2 million. This expense will be recognized over 51 months on average for stock options and over 45 months on average for restricted stock units, assuming no change in the remeasurement value of grants made to non-employees in this calculation.

We treat stock-based compensation awards granted to employees of Cellectis as deemed dividends. We recorded deemed dividends of $0.4 million for the three months ended March 31, 2019, and $0.7 million for the three months ended March 31, 2018.

Cellectis Equity Incentive Plan

Prior to 2018 Cellectis granted stock options to our employees. Compensation costs related to these grants have been recognized in the statements of operations with a corresponding credit to stockholders’ equity, representing Cellectis’ capital contribution to us. The fair value of each stock option was estimated at the grant date using the Black-Scholes option pricing model.

We recognized stock-based compensation expense related to Cellectis’ grants of $0.1 million for the three months ended March 31, 2018. Expenses in 2019 were immaterial.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	6. INCOME TAXES We provide for a valuation allowance when it is more likely than not that we will not realize a portion of the deferred tax assets. We have established a full valuation allowance for deferred tax assets due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, we have not reflected any benefit of such deferred tax assets in the accompanying financial statements. As of March 31, 2019, there were no material changes to what we disclosed regarding tax uncertainties or penalties as of December 31, 2018.

Leases, Other Commitments, and Contingencies	3 Months Ended
Leases, Other Commitments, and Contingencies	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Leases, Other Commitments, and Contingencies	7. LEASES, OTHER COMMITMENTS, AND CONTINGENCIES *Litigation and Claims* We are not currently a party to any material pending legal proceeding. *Leases* We lease our headquarters facility, office equipment, and other items. Our headquarters lease involved the sale of land and improvements to a third party who then constructed the facility. The lease term is twenty years and we hold four five-year options to extend the lease. Rent expense from all operating leases was $49 thousand for three months ended 2019, and $81 thousand for three months ended 2018. *Sale-Leaseback of Equipment* In December 2018 we consummated a sale-leaseback transaction with a third party to finance equipment. The lease has a term of four years and we may add up to $1.1 million of future equipment purchases to the financing agreement. We were required to deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. At March 31, 2019, this restricted cash totaled $1.5 million. *Other Commitments* As of March 31, 2019, we have committed to purchase grain from farmers at dates throughout 2019 and 2020 aggregating $19.7 million using commodity futures market prices, other payments to growers and estimated yields per acre. This amount is not recorded in the financial statements because we have not taken delivery of the grain as of that date.

Employee Benefit Plan	3 Months Ended
Employee Benefit Plan	Mar. 31, 2019
Postemployment Benefits [Abstract]
Employee Benefit Plan	8. EMPLOYEE BENEFIT PLAN We provide a 401(k) defined contribution plan for all regular full-time employees who have completed three months of service. We match employee contributions up to certain amounts and those matching contributions vest immediately. Our expense was $56 thousand for the three months ended March 31, 2019, and $49 thousand for the three months ended March 31, 2018.

Supplemental Information

3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental Information

9. SUPPLEMENTAL INFORMATION

Certain statements of operations amounts are as follows:


	Three months ended March 31,
In Thousands	2019		2018

Stock compensation expense:
Research and development	$	240	$	(437)
Selling, general and administrative		1,316		369

Total	$	1,556	$	(68)


	Three months ended March 31,
In Thousands	2019		2018

Interest expense	$	(370)	$	(235)
Interest income		542		167

Interest, net	$	172	$	(68)

Certain statements of cash flows amounts are as follows:


	As of March 31,
In Thousands	2019		2018

Cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	84,231	$	50,703
Restricted cash, current		381		-
Non-current restricted cash		1,120		-

Total	$	85,732	$	50,703


	As of March 31,

In Thousands	2019		2018

Non-cash additions to land, buildings and equipment	$	-	$	4,529
Deferred cost in accounts payable and accrued liabilities		-	$	417

Total	$	-	$	4,946

Segment Information	3 Months Ended
Segment Information	Mar. 31, 2019
Segment Reporting [Abstract]
Segment Information	10. Segment Information We operate in a single reportable segment, food ingredients. Our current commercial focus is North America. Our major product categories are High Oleic Soybean Oil and High Oleic Soybean Meal.

Basis of Presentation (Policies)	3 Months Ended
Basis of Presentation (Policies)	Mar. 31, 2019
Accounting Policies [Abstract]
Inventory	*Inventory* Inventories are recorded at the lower of cost or net realizable value and include all costs of seed production and grain we purchase as well as costs to transport and process the grain into finished products. Consideration we receive from our growers to purchase seed is reduction in the cost of inventory. We evaluate inventory balances for obsolescence quarterly using projected selling prices for our products, market prices for the underlying agricultural markets, the age of products, and other factors considering our limited operating history. Effective January 1, 2019, we designated all seed and grain production agreements as normal purchases and as a result no longer consider these agreements to be accounting derivatives. As a result, we no longer reflect these agreements at fair value. As of that date, any mark-to-market gains or losses were frozen on our balance sheet and will be reflected in inventory upon delivery as part of the cost of the associated grain. Prior to the commercialization of our High Oleic Soybean Products in late February 2019, we expensed all costs associated with the production of seed and acquisition of grain, net of proceeds from seed sales, as research and development (R&D) expense.
Revenue Recognition	*Revenue Recognition* We recognize sales revenue at the point in time control transfers to the customer, which is based on shipping terms. Sales include shipping and handling charges if billed to the customer and are reported net of trade promotion and other costs, including estimated allowances for returns, unsalable product, and prompt pay discounts. Sales, use, value-added and other excise taxes are not recognized in revenue. Trade promotions are recorded based on estimated participation and performance levels for offered programs at the time of sale. We generally do not allow a right of return. However, on a limited case-by-case basis with prior approval, we may allow customers to return product. We also recognize revenue from R&D agreements and license agreements. Revenues from R&D agreements may consist of nonrefundable up-front payments, milestone payments, royalties, and services. In addition, we may license our technology to third parties, which may or may not be part of an R&D agreement. Nonrefundable up-front payments are deferred and recognized as revenue over the term of the R&D agreement. If an R&D agreement is terminated before the original term of the agreement is fulfilled, all remaining deferred revenue is recognized at termination. Milestone payments represent amounts received from our R&D partners, the receipt of which is dependent upon the achievement of certain scientific, regulatory, or commercial milestones. We recognize milestone payments when the triggering event has occurred, there are no further contingencies or services to be provided with respect to that event, and the counterparty has no right to refund of the payment.
Stock Based Compensation	*Stock-Based Compensation* We measure employee stock-based awards at grant-date fair value and record compensation expense over the vesting period of the award. Grants to nonemployees were previously remeasured each reporting period. Following the adoption of the new accounting pronouncement as discussed below, as of January 1, 2019, we no longer remeasure these awards as the fair value is determined on the grant date
Recently Adopted Accounting Pronouncements	*Recently Adopted Accounting Pronouncements* In the first quarter of 2019, we adopted new accounting requirements for recognition of revenue from contracts with customers. We adopted these requirements using the cumulative effect approach. The adoption did not have an impact on our financial statements. In the first quarter of 2019, we adopted new accounting requirements for share-based payment transactions for acquiring goods and services from nonemployees. The adoption did not have an impact on our financial statements as each of the share-based payment awards granted to nonemployees had a measurement date upon grant, and thus no cumulative adjustment to retained earnings was required.

Financial Instruments, Fair Value, and Concentrations of Credit Risk (Tables)

3 Months Ended

Mar. 31, 2019

Text Block [Abstract]

Summary of Fair Value Measurements and Financial Statement Presentation

The fair values of our assets, liabilities, and derivative positions recorded at fair value and their respective levels in the fair value hierarchy as of December 31, 2018, were as follows:


	December 31, 2018								December 31, 2018
	Fair Values of Assets								Fair Values of Liabilities
In Thousands	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total

Other items reported at fair value:
Forward Purchase Contracts (a)	$	-	$	1	$	-	$	1	$	-	$	248	$	-	$	248

Total	$	-	$	1	$	-	$	1	$	-	$	248	$	-	$	248

(a)	The fair value for forward purchase contracts is estimated based on commodity futures market prices.

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

Basic and diluted loss per share were calculated using the following:

All outstanding stock options and restricted stock units are excluded from the calculation since they are anti-dilutive.


	Three months ended March 31,
In Thousands, Except Share Data and Per Share Amounts	2019		2018

Net loss	$	(7,375)	$	(4,370)
Average number of common shares—basic and diluted EPS		32,677,944		27,851,162

Loss per share—basic and diluted	$	(0.23)	$	(0.16)


	2019		2018

Anti-dilutive stock options and restricted stock units		4,385,595		4,917,164

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model

The estimated fair values of stock options granted and the assumptions used for the Black-Scholes option pricing model were as follows:


	Three months ended March 31,

	2019		2018

Estimated fair values of stock options granted	$	9.45	$	10.39
Assumptions:
Risk-free interest rate		2.5%		2.5% - 2.7%
Expected volatility		78.9%		40.9% - 53.7%
Expected term (in years)		6.9 years		6.5 – 9.2 years

Summary of Stock Option Activity

Information on stock option activity follows:


	Options Exercisable		Weighted- Average Exercise Price Per Share		Options Outstanding			Weighted- Average Exercise Price Per Share

Balance as of December 31, 2018		1,278,038	$	7.45		3,201,887			$ 10.67
Granted						180,000			13.01
Exercised						(34,402	)		3.63
Forfeited or expired						(2,205	)		13.29

Balance as of March 31, 2019		1,340,631	$	7.59		3,345,280			$ 10.87

Schedule of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised

Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows:


	Three months ended March 31,
In Thousands	2019		2018

Net cash proceeds	$	125	$	714

Intrinsic value of options exercised	$	353	$	3,260

Summary of Activity of Restricted Stock Units

Information on restricted stock unit activity follows:


	Number of Restricted Stock Units Outstanding			Weighted-Average Grant Date Fair Value

Unvested balance at December 31, 2018		1,051,414		$	10.15
Vested		(8,894	)		14.91
Unvested balance at March 31, 2019		1,042,520		$	9.64

Supplemental Information (Tables)

3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Certain Statements of Operations Amounts

Certain statements of operations amounts are as follows:


	Three months ended March 31,
In Thousands	2019		2018

Stock compensation expense:
Research and development	$	240	$	(437)
Selling, general and administrative		1,316		369

Total	$	1,556	$	(68)


	Three months ended March 31,
In Thousands	2019		2018

Interest expense	$	(370)	$	(235)
Interest income		542		167

Interest, net	$	172	$	(68)

Schedule of Statements of Certain Statements of Cash Flows Amounts

Certain statements of cash flows amounts are as follows:


	As of March 31,
In Thousands	2019		2018

Cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	84,231	$	50,703
Restricted cash, current		381		-
Non-current restricted cash		1,120		-

Total	$	85,732	$	50,703


	As of March 31,

In Thousands	2019		2018

Non-cash additions to land, buildings and equipment	$	-	$	4,529
Deferred cost in accounts payable and accrued liabilities		-	$	417

Total	$	-	$	4,946

Financial Instruments, Fair Value, and Concentrations of Credit Risk - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Fair Value, Concentration of Risk, Financial Assets, Balance Sheet Groupings [Abstract]
Fair value of financing leases	$ 15.6	$ 15.8
Financing lease obligations	$ 18.4	$ 18.5

Financial Instruments, Fair Value, and Concentrations of Credit Risk - Summary of Fair Value Measurements and Financial Statement Presentation (Detail)
$ in Thousands

Dec. 31, 2018

USD ($)

Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]

Fair Values of Assets

$ 1

Fair Values of Liabilities

248

Forward Purchase Contracts [Member]

Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]

Fair Values of Assets

^[1]

Fair Values of Liabilities

248

^[1]

Level 2 [Member]

Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]

Fair Values of Assets

Fair Values of Liabilities

248

Level 2 [Member] | Forward Purchase Contracts [Member]

Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]

Fair Values of Assets

^[1]

Fair Values of Liabilities

$ 248

^[1]

[1]	The fair value for forward purchase contracts is estimated based on commodity futures market prices.

Related-Party Transactions - Additional Information (Detail) - Cellectis [Member] - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Related Party Transaction [Line Items]
Minimum net worth required	$ 300,000,000
General and Administrative Expense [Member]
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	$ 400,000	$ 600,000

Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Earnings Per Share [Abstract]
Net loss	$ (7,375)	$ (4,370)
Average number of common shares-basic and diluted EPS	32,677,944	27,851,162
Loss per share-basic and diluted	$ (0.23)	$ (0.16)
Anti-dilutive stock options and restricted stock units	4,385,595	4,917,164

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Stock-Based Compensation - Additional Information (Detail)	Mar. 31, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares available for grant	896,478
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares available for grant	4,159,660

Stock-Based Compensation - Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of stock options granted	$ 9,450	$ 10,390
Risk-free interest rate, minimum	2.50%	2.50%
Risk-free interest rate, maximum		2.70%
Expected volatility, minimum	78.90%	40.90%
Expected volatility, maximum		53.70%
Expected term (in years)	6 years 10 months 24 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)		6 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)		9 years 2 months 12 days

Stock-Based Compensation - Stock Options - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,556	$ (68)
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option expiration period	10 years
Stock option, vesting period	6 years
Aggregate intrinsic value of options outstanding and exercisable	$ 23,300
Weighted average remaining contractual term	8 years
Stock-based compensation expense	$ 800	$ 100
2017 Omnibus Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options priced at fair market value, percent	100.00%

Stock-Based Compensation - Summary of Stock Option Activity (Detail)	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Exercisable, Beginning Balance \| shares	1,278,038
Options Exercisable, Ending Balance \| shares	1,340,631
Weighted-Average Exercise Price Per Share, Beginning Balance \| $ / shares	$ 7.45
Weighted-Average Exercise Price Per Share, Ending Balance \| $ / shares	$ 7.59
Options Outstanding, Beginning Balance \| shares	3,201,887
Options Outstanding, Granted \| shares	180,000
Options Outstanding, Exercised \| shares	(34,402)
Options Outstanding, Forfeited or expired \| shares	(2,205)
Options Outstanding, Ending Balance \| shares	3,345,280
Weighted-Average Exercise Price Per Share, Beginning Balance \| $ / shares	$ 10.67
Weighted-Average Exercise Price Per Share, Granted \| $ / shares	13.01
Weighted-Average Exercise Price Per Share, Exercised \| $ / shares	3.63
Weighted-Average Exercise Price Per Share, Forfeited or expired \| $ / shares	13.29
Weighted-Average Exercise Price Per Share, Ending Balance \| $ / shares	$ 10.87

Stock-Based Compensation - Summary of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Net cash proceeds	$ 125	$ 714
Intrinsic value of options exercised	$ 353	$ 3,260

Stock-Based Compensation - Restricted Stock Units - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to to non-vested stock options and restricted stock units	$ 10.2
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock, vesting period	6 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value vested	$ 0.1	$ 0.0
Unrecognized stock-based compensation expense, expected recognition weighted-average period	45 months
Restricted Stock Units [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock, vesting period	5 years
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense, expected recognition weighted-average period	51 months
Nonemployee Restricted Stock Units [Member] \| Cellectis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends	$ 0.4	$ 0.7

Stock-Based Compensation - Summary of Activity of Restricted Stock Units (Detail) - Restricted Stock Units [Member]	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units outstanding, Unvested beginning balance \| shares	1,051,414
Number of restricted stock units outstanding, Vested \| shares	(8,894)
Number of restricted stock units outstanding, Unvested ending balance \| shares	1,042,520
Weighted-average grant date fair value, Unvested beginning balance \| $ / shares	$ 10.15
Weighted-average grant date fair value, Vested \| $ / shares	14.91
Weighted-average grant date fair value, Unvested ending balance \| $ / shares	$ 9.64

Stock-Based Compensation - Cellectis Equity Incentive Plan - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,556	$ (68)
Cellectis [Member] \| Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 100

Leases, Other Commitments, and Contingencies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2019 USD ($) Options	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)
Other Commitments [Line Items]
Lease term	20 years
Number of lease extension options \| Options	4
Extension term of lease agreement	5 years
Total rent expense under operating lease	$ 49,000	$ 81,000
Forward purchase commitment amount	19,700,000
Equipment [Member]
Other Commitments [Line Items]
Lease term			4 years
Restricted cash	$ 1,500,000
Maximum [Member] \| Equipment [Member]
Other Commitments [Line Items]
Sale-leaseback that can be financed or leased			$ 1,100,000

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Compensation Related Costs [Abstract]
Defined contribution plan description	We provide a 401(k) defined contribution plan for all regular full-time employees who have completed three months of service.
Expenses to the plan by employer	$ 56	$ 49

Condensed Financial Statements - Summary of Certain Statements of Operations Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ 1,556	$ (68)
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	240	(437)
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ 1,316	$ 369

Condensed Financial Statements - Summary of Components of Interest, Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Condensed Financial Information Disclosure [Abstract]
Interest expense	$ (370)	$ (235)
Interest income	542	167
Interest, net	$ 172	$ (68)

Condensed Financial Statements - Summary of Statements of Certain Statements of Cash Flows Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Information Disclosure [Abstract]
Cash and cash equivalents	$ 50,703	$ 84,231	$ 93,794
Restricted cash, current		381	381
Non-current restricted cash		1,120	1,113
Cash, cash equivalents, and restricted cash	50,703	$ 85,732	$ 95,288	$ 56,664
Non-cash additions to land, buildings and equipment	4,529
Deferred cost in accounts payable and accrued liabilities	417
Total	$ 4,946

Segment Information - Additional Information (Detail)	3 Months Ended
Segment Information - Additional Information (Detail)	Mar. 31, 2019 Segment
Segment Reporting [Abstract]
Number of reportable segments	1